Welcome to our dedicated page for LENSAR news (Ticker: LNSR), a resource for investors and traders seeking the latest updates and insights on LENSAR stock.
LENSAR, Inc. (LNSR) is at the forefront of next-generation femtosecond laser technology, specializing in refractive cataract surgery. The company's flagship product, the LENSAR Laser System, offers unmatched precision and accuracy, optimizing visual outcomes for cataract patients. This cutting-edge system features the proprietary Augmented Reality™, LENSAR’s advanced 3-D imaging, measurement, and guidance technology. By providing high-resolution ocular images in a single scan, the system ensures precise surgical incisions and treatments, all within a single procedure room.
Unlike other femtosecond cataract lasers, the LENSAR Laser System is specifically built for refractive cataract surgery. Designed from the ground up with the needs of cataract surgeons in mind, the system integrates a suite of proprietary technologies aimed at improving visual outcomes, efficiency, and reproducibility. These technologies include Streamline IV and IntelliAxis, which assist surgeons with imaging, procedure planning, and precision.
At its core, LENSAR, Inc. is a commercial-stage medical device company committed to revolutionizing refractive eye surgery. Their product portfolio extends beyond the laser system to include the associated consumable components, such as the disposable patient interface device (PID) kits and procedure licenses necessary for each surgical procedure.
LENSAR's focus on innovation doesn't stop at technology. They are dedicated to building a vibrant team of talented and motivated individuals who share their passion for making a significant impact on patients' lives. The company continues to push the boundaries of what's possible in refractive cataract surgery, ensuring that their technology remains at the cutting edge of medical advancements.
LENSAR, a medical technology company, reported its financial results for Q4 and full year 2022. Total revenue for Q4 decreased by 9% to $10.2 million, primarily due to lower procedure revenue in South Korea. Despite this, the year-end revenue of $35.4 million represented a 3% increase from 2021. The company installed ten ALLY Adaptive Cataract Treatment Systems by year-end and signed contracts for six more. Selling, general and administrative expenses rose by 24%, reflecting increased marketing efforts. LENSAR aims for over 20% revenue growth in 2023 as it fully launches the ALLY System.
LENSAR, Inc. (NASDAQ: LNSR), a leader in medical technology focused on femtosecond laser surgical solutions for cataracts, will release its fourth quarter and full year 2022 financial results on March 16, 2023, before the market opens. A conference call will follow at 8:30 am ET the same day to discuss the results and corporate updates. Interested parties can join the call by dialing (888) 886 7786 for domestic or (416) 764 8658 for international access, using conference ID 94867603. The company’s innovative ALLY® Adaptive Cataract Treatment System aims to enhance surgical efficiency and outcomes.
LENSAR, Inc. (NASDAQ: LNSR) reported preliminary unaudited revenue of approximately $10.2 million for Q4 2022, down from $11.2 million in the same quarter of 2021, attributed to lower procedure revenue in South Korea. However, Q4 revenue shows a 32% increase from Q3 2022. Total revenue for 2022 reached about $35.4 million, slightly up from $34.5 million in 2021. The company installed ten ALLY Systems in 2022, with contracts for six more signed for installation in H1 2023. Cash and cash equivalents were approximately $14.7 million as of December 31, 2022, reflecting the company's ongoing transition to its next-generation technology.
LENSAR, a medical technology company specializing in femtosecond laser surgical solutions for cataracts, announced that CEO Nick Curtis will present at two investor conferences. The presentations include the BTIG Ophthalmology Day on November 29 at 3:00 p.m. ET and the Piper Sandler 34th Annual Healthcare Conference on November 30 at 2:50 p.m. ET. The live presentation can be accessed on LENSAR's website, with the Piper Sandler event available for a month afterward.
LENSAR, a leader in advanced laser surgical solutions for cataracts, reported its Q3 2022 results, showing total revenue of $7.7 million, a 6% decline from $8.3 million in Q3 2021. Despite a 46% drop in international procedures, U.S. volumes rose 9%. Operating expenses decreased, contributing to a reduced net loss of $4 million ($0.39 per share), down from $6.2 million ($0.65 per share) a year earlier. The ALLY System's U.S. launch is pivotal, with strong surgeon feedback. Cash reserves as of September 30, 2022, stood at $19.3 million, providing operational funding through 2024.
LENSAR, Inc. (NASDAQ: LNSR) will release its third quarter 2022 financial results before market open on November 9, 2022. A conference call to discuss these results and recent corporate developments is scheduled for 8:30 am ET on the same day. LENSAR specializes in advanced femtosecond laser surgical solutions for cataracts, utilizing its next-generation ALLY™ Adaptive Cataract Treatment System. This innovative system integrates proprietary imaging with a dual-pulse femtosecond laser, designed to enhance operational efficiencies in cataract surgeries.
LENSAR, Inc. (NASDAQ: LNSR), a medical technology firm specializing in femtosecond laser solutions for cataract treatment, has announced its application for certification of the ALLY™ Adaptive Cataract Treatment System in the European Union. Following FDA clearance in June 2022 and a successful U.S. launch, this step aims to expand global access to ALLY. The system enhances cataract surgery efficiency by integrating Adaptive Intelligence™ to optimize surgical parameters. If certified, LENSAR plans to utilize a distributor network for its EU launch.
LENSAR, Inc. (NASDAQ: LNSR) has announced the first commercial use of its ALLY™ Adaptive Cataract Treatment System at The Eye Institute of West Florida. Dr. Robert Weinstock performed 15 surgeries using the ALLY system, showcasing its advanced capabilities aimed at enhancing cataract surgery efficiency and patient outcomes. Since receiving FDA clearance in June 2022, LENSAR plans to install 8 to 12 ALLY systems as part of a controlled launch. The system's design focuses on improving the surgical experience for both patients and surgeons, positioning LENSAR for growth in the cataract treatment market.
LENSAR, a medical technology company, announced FDA clearance for its ALLY Adaptive Cataract Treatment System, marking a significant milestone. In Q2 2022, total revenue increased to $8.0 million, up 1% from Q2 2021, driven by a rise in U.S. procedure volumes despite lower LENSAR Laser System sales. Operating expenses rose by 37% to $7.6 million, attributed to higher marketing costs. The net loss for Q2 2022 widened to $6.8 million, compared to $4.4 million the previous year. Cash reserves stood at $25.2 million, with sufficient funds projected to sustain operations into 2024.
LENSAR, Inc. (NASDAQ: LNSR) will release its second quarter 2022 financial results on August 8, 2022, before market open. A conference call and webcast will follow at 8:30 am ET on the same day, where management will discuss the financial results and corporate highlights. The company specializes in advanced femtosecond laser surgical solutions for cataracts, notably with its ALLY™ Adaptive Cataract Treatment System, which enhances operational efficiency and surgical outcomes.
FAQ
What is the current stock price of LENSAR (LNSR)?
What is the market cap of LENSAR (LNSR)?
What does LENSAR, Inc. specialize in?
What is the LENSAR Laser System?
What makes the LENSAR Laser System unique?
What is Augmented Reality™ in the context of LENSAR?
What is included in LENSAR's product portfolio?
What are the consumable components of the LENSAR Laser System?
What is the primary focus of LENSAR, Inc.?
How does LENSAR contribute to the surgical process?
How does LENSAR ensure the effectiveness of its technology?
What drives the success of LENSAR, Inc.?
